Analysts From Major Brokerage Firms Release Report On Eli Lilly and Company (LLY)

The stock of Eli Lilly and Company (NYSE:LLY) increased by $8.52 on Wednesday to $305.86, up 2.87 percent. The last five days have seen an average of 3,130,910 shares of common stock traded. 10 times new highs were reached in the current year, with a gain of $28.78. The average number of shares traded over the last 20 days was 3,184,363, while the average volume over the last 50 days totaled 2,960,581.

LLY stock appreciated 3.87% since last month. On 06/16/22, the company’s shares reached a one-month low of $283.11. The stock touched a high of $324.08 on 05/27/22, after rallying from a low of $217.00 in 52 weeks. The price of LLY stock has risen by 7.65% or $28.78 this year, reaching a new high 10 times. Still, the stock price is down -5.62% from the 52-week high.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored


Insider Transactions

There have been 21 days since Eli Lilly and Company (LLY) last reported insider trading activity on Jun 01. On Jun 01, Chief Accounting Officer Zakrowski Donald A sold 1,000 shares at $313.44 each. This transaction resulted in the insider making $313,440. On May 27, LILLY ENDOWMENT INC sold 200,000 shares at a price of US$318.98. After the transaction, the insider now owns 104,833,810 shares. 10% Owner LILLY ENDOWMENT INC had earlier sold 178,390 shares on May 26 for $311.27 a share. The transaction was completed for $55,526,821.

Valuation Metrics

Eli Lilly and Company (LLY) has a trailing price-to-earnings (P/E) ratio of 44.12. Beta for the stock is 0.45. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 9.54, the price-to-book (PB) ratio of 28.78, and the price-to-cash flow ratio of 80.16.

Company paid $0.98 per share in dividends, remained unchanged from $0.98 last year. A $0.13 dividend increase was reported on Monday December 13 2021.

Financial Health

For the three months ended March 30, Eli Lilly and Company’s quick ratio was 1.00, while its current ratio was 1.30, indicating its ability to pay off its debt. The company’s long-term debt to equity ratio for the quarter ending March 30 is 1.62, and the total debt to equity ratio is 1.77. As far as profitability goes, gross margin for the trailing twelve months is 74.40% percent. Eli Lilly and Company’s operating margin stood at 24.60% for the same period. Based on annual data, it had gross profit of $21.01 billion and revenue of $28.32 billion.

Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. LLY’s return on assets (ROA) during the last 12 months has been 12.80%. There was a 20.80% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was 75.40%.

Earnings Surprise

According to Eli Lilly and Company’s quarterly financial report for the quarter that ended March 30, it had $15.15 billion in total debt versus $109.1 million in cash and short-term investments. A lower net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $7.81 billion, while revenues rose by 12.86% to $8.0 billion. It was predicted that Eli Lilly and Company’s quarterly earnings would be $2.49, but it ended up being $2.17, beating the consensus by 14.70%. EBITDA was $2.84 billion for the quarter. At the end of Eli Lilly and Company’s most recent quarter ended March 30, its liabilities totaled 37.46 billion, while its total debt was $16.55 billion. Equity owned by shareholders amounts to $950.16 million.

Technical Picture

Here’s a quick look at Eli Lilly and Company’s (LLY) price momentum from a technical perspective. As of 21 June, the RSI 9-day stood at 57.56%, suggesting the stock is Neutral, with a 30.75% historical volatility rate.

The stochastic %K and %D were 44.52% and 30.86% respectively, while the average true range (ATR) was 9.14. Based on the 14-day stochastic reading of 67.58%, the RSI (14) reading is 54.75%. On the 9-day MACD Oscillator, the stock is at 2.57, and the 14-day reading is at -1.51.

Analyst Ratings

In its analyst report released on May 23, 2022, SVB Leerink began covering Eli Lilly and Company (NYSE: LLY). The stock was rated as an Outperform by the brokerage firm. Analysts have assigned Eli Lilly and Company (LLY) an Overweight rating. LLY is a stock that is recommended for selling by 0 brokerage firms, while 7 companies recommend holding. The stock is underweighted by 2 analysts. Among the analysts who rate the stock, 2 rates it overweight and 14 others recommend it as a buy.

What is LLY’s price target for the next 12 months?

The current consensus forecast for the stock is between $202.00 and $369.00, with a median target price of $333.00. In analyzing these forecasts, the average price target given by analysts for Eli Lilly and Company (LLY) is $318.52.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Hot Topics

Related Articles

174452

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

The 5 Best Growth Stocks 2022

100% free. stop anytime no spam